Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7198457 plus pembrolizumab versus pembrolizumab in previously untreated advanced melanoma
2018-001773-24Phase 2Unknown
- Sponsor
- Genentech
- Start
- Jun 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in melanoma comparing RO7198457 plus pembrolizumab with Pembrolizumab monotherapy (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
autogene cevumeranpembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2018-001773-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001773-24.